111, Inc. Sponsored ADR (NASDAQ:YI) Short Interest Update

111, Inc. Sponsored ADR (NASDAQ:YIGet Free Report) saw a significant decrease in short interest in February. As of February 13th, there was short interest totaling 25,958 shares, a decrease of 33.5% from the January 29th total of 39,019 shares. Based on an average trading volume of 61,821 shares, the short-interest ratio is presently 0.4 days. Approximately 0.5% of the company’s shares are short sold. Approximately 0.5% of the company’s shares are short sold. Based on an average trading volume of 61,821 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 111 in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on 111

111 Stock Down 2.1%

NASDAQ YI opened at $7.91 on Monday. The stock has a market capitalization of $68.34 million, a PE ratio of -9.42 and a beta of 0.54. 111 has a 12-month low of $2.48 and a 12-month high of $11.35. The company has a 50 day moving average price of $5.62 and a two-hundred day moving average price of $5.09.

111 (NASDAQ:YIGet Free Report) last released its quarterly earnings results on Wednesday, December 17th. The company reported ($1.20) earnings per share for the quarter. The firm had revenue of $421.49 million for the quarter.

About 111

(Get Free Report)

111, Inc (NASDAQ: YI) is a leading online pharmacy e-commerce platform in China, operating under the brand 111.com. The company provides consumers with a comprehensive selection of pharmaceutical and healthcare products through its proprietary digital channels, including a website and mobile applications. By integrating online ordering, prescription management, and direct-to-consumer delivery, 111, Inc aims to streamline the purchase of medicines and health-related goods for customers nationwide.

111, Inc’s product portfolio encompasses prescription and over-the-counter drugs, nutritional supplements, vitamins, maternal and child care items, personal care products, and beauty goods.

Further Reading

Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.